GLPwatch

Use of semaglutide and tirzepatide among people with multiple sclerosis.

Mult Scler · 2026

Last updated 2026-05-28

In a survey of 4,181 people with multiple sclerosis, 7.4% had ever used GLP-1 drugs like semaglutide or tirzepatide, and 5.5% were currently using them. Those who had used them were younger and had more conditions like heart disease or diabetes. However, 40% of those who had never used these drugs had a medical reason that would typically make them candidates for this treatment.

AI summary of the abstract below.

JournalMult Scler, 2026
Citations0
Molecules semaglutide, tirzepatide

Abstract

BACKGROUND AND OBJECTIVES: Little is known about glucagon-like peptide-1 receptor agonists (GLP1RAs) use in multiple sclerosis. We described the frequency and characteristics associated with use. METHODS: A cross-sectional survey of NARCOMS Registry participants captured use of GLP1RAs semaglutide and tirzepatide. Multivariable logistic regression explored factors associated with use. RESULTS: Among 4181 eligible participants, 7.4% had ever and 5.5% currently used these GLP1RAs. Ever users were younger and had more cardiometabolic conditions. 37.3% of never users had an indication for GLP1RAs. DISCUSSION: Despite 40% having an indication for taking GLP1RAs, a small percentage of surveyed persons with multiple sclerosis used them.

Verbatim abstract via PubMed 42053291 ↗

Related research